{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:36:40Z","timestamp":1786981000696,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Research Foundation of Korea (NRF) grant funded by the Korea government","award":["2022R1F1A1064215"],"award-info":[{"award-number":["2022R1F1A1064215"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10620-025-09091-y","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T22:52:49Z","timestamp":1749077569000},"page":"3041-3055","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Combination of PF-543 and TRAIL Effectively Induces Apoptotic Cell Death and Inhibits Stem Cell-Like Properties Through the SPHK1\/S1PR1\/STAT3 Pathway in TRAIL-Resistant Colorectal Cancer Cells"],"prefix":"10.1007","volume":"70","author":[{"given":"Se Lim","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Woo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Chul","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Young","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"9091_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u2013263.","journal-title":"CA Cancer J Clin."},{"key":"9091_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.critrevonc.2018.09.017","volume":"132","author":"S Norouzi","year":"2018","unstructured":"Norouzi S, Gorgi Valokala M, Mosaffa F, Zirak MR, Zamani P, Behravan J. Crosstalk in cancer resistance and metastasis. Crit Rev Oncol Hematol. 2018;132:145\u2013153.","journal-title":"Crit Rev Oncol Hematol."},{"key":"9091_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/jcb.240560108","volume":"56","author":"RS Kerbel","year":"1994","unstructured":"Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: are they linked phenotypes? J Cell Biochem. 1994;56:37\u201347.","journal-title":"J Cell Biochem."},{"key":"9091_CR4","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.3748\/wjg.v29.i9.1395","volume":"29","author":"S Al Bitar","year":"2023","unstructured":"Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond. World J Gastroenterol. 2023;29:1395\u20131426.","journal-title":"World J Gastroenterol."},{"key":"9091_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575:299\u2013309.","journal-title":"Nature."},{"key":"9091_CR6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467\u20131480.","journal-title":"Lancet."},{"key":"9091_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1535-7163.MCT-11-0434","volume":"11","author":"CT Hellwig","year":"2012","unstructured":"Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based combination therapies. Mol Cancer Ther. 2012;11:3\u201313.","journal-title":"Mol Cancer Ther."},{"key":"9091_CR8","first-page":"1162","volume":"61","author":"C Hao","year":"2001","unstructured":"Hao C, Beguinot F, Condorelli G et al. Induction and intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) mediated apotosis in human malignant glioma cells. Cancer Res. 2001;61:1162\u20131170.","journal-title":"Cancer Res."},{"key":"9091_CR9","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.21873\/anticanres.15240","volume":"41","author":"MW Shin","year":"2021","unstructured":"Shin MW, Kim SL, Yang HC et al. The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells. Anticancer Res. 2021;41:4353\u20134364.","journal-title":"Anticancer Res."},{"key":"9091_CR10","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1007\/s10620-024-08569-5","volume":"69","author":"SL Kim","year":"2024","unstructured":"Kim SL, Shin M, Jin BC, Seo S, Ha GW, Kim SW. Acquired Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Resistance of Human Colorectal Cancer Cells Is Linked to Histone Acetylation and Is Synergistically Ameliorated by Combination with HDAC Inhibitors. Dig Dis Sci. 2024;69:3305\u20133317.","journal-title":"Dig Dis Sci."},{"key":"9091_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature13475","volume":"510","author":"M Maceyka","year":"2014","unstructured":"Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014;510:58\u201367.","journal-title":"Nature."},{"key":"9091_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pharmthera.2018.10.011","volume":"195","author":"X Zheng","year":"2019","unstructured":"Zheng X, Li W, Ren L et al. The sphingosine kinase-1\/sphingosine-1-phosphate axis in cancer: Potential target for anticancer therapy. Pharmacol Ther. 2019;195:85\u201399.","journal-title":"Pharmacol Ther."},{"key":"9091_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jbior.2017.09.006","volume":"68","author":"NJ Pyne","year":"2018","unstructured":"Pyne NJ, El Buri A, Adams DR, Pyne S. Sphingosine 1-phosphate and cancer. Adv Biol Regul. 2018;68:97\u2013106.","journal-title":"Adv Biol Regul."},{"key":"9091_CR14","first-page":"5290","volume":"11","author":"YJ Su","year":"2018","unstructured":"Su YJ, Zhang JX, Li SM. Relationship of vasculogenic mimicry, SphK1 expression, and Cx43 expression to metastasis and prognosis in colorectal cancer. Int J Clin Exp Pathol. 2018;11:5290\u20135299.","journal-title":"Int J Clin Exp Pathol."},{"key":"9091_CR15","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1002\/cam4.2041","volume":"8","author":"S Yin","year":"2019","unstructured":"Yin S, Miao Z, Tan Y et al. SPHK1-induced autophagy in peritoneal mesothelial cell enhances gastric cancer peritoneal dissemination. Cancer Med. 2019;8:1731\u20131743.","journal-title":"Cancer Med."},{"key":"9091_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1158\/0008-5472.CAN-17-1423","volume":"78","author":"M Nagahashi","year":"2018","unstructured":"Nagahashi M, Yamada A, Katsuta E et al. Targeting the SphK1\/S1P\/S1PR1 Axis That Links Obesity, Chronic Inflammation, and Breast Cancer Metastasis. Cancer Res. 2018;78:1713\u20131725.","journal-title":"Cancer Res."},{"key":"9091_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119846","volume":"1871","author":"H Liu","year":"2024","unstructured":"Liu H, Li X, Liu W et al. DHRS2-induced SPHK1 downregulation contributes to the cell growth inhibition by Trichothecin in colorectal carcinoma. Biochim Biophys Acta Mol Cell Res. 2024;1871:119846.","journal-title":"Biochim Biophys Acta Mol Cell Res."},{"key":"9091_CR18","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3892\/or.2014.3391","volume":"32","author":"H Xiong","year":"2014","unstructured":"Xiong H, Wang J, Guan H et al. SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating Bim via stimulating Akt\/FoxO3a signaling. Oncol Rep. 2014;32:1369\u20131373.","journal-title":"Oncol Rep."},{"key":"9091_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102109","author":"Y Bao","year":"2017","unstructured":"Bao Y, Guo Y, Zhang C, Fan F, Yang W. Sphingosine Kinase 1 and Sphingosine-1-Phosphate Signaling in Colorectal Cancer. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18102109.","journal-title":"Int J Mol Sci."},{"key":"9091_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_217","volume":"259","author":"M Maceyka","year":"2020","unstructured":"Maceyka M, Rohrbach T, Milstien S, Spiegel S. Role of Sphingosine Kinase 1 and Sphingosine-1-Phosphate Axis in Hepatocellular Carcinoma. Handb Exp Pharmacol. 2020;259:3\u201317.","journal-title":"Handb Exp Pharmacol."},{"key":"9091_CR21","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.3892\/mmr.2020.11295","volume":"22","author":"X Ren","year":"2020","unstructured":"Ren X, Su C. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma. Mol Med Rep. 2020;22:2183\u20132190.","journal-title":"Mol Med Rep."},{"key":"9091_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41420-025-02309-y","volume":"11","author":"K Teng","year":"2025","unstructured":"Teng K, Ma H, Gai P, Zhao X, Qi G. SPHK1 enhances olaparib resistance in ovarian cancer through the NFkappaB\/NRF2\/ferroptosis pathway. Cell Death Discov. 2025;11:29.","journal-title":"Cell Death Discov."},{"key":"9091_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12935-024-03221-8","volume":"24","author":"SS Alkafaas","year":"2024","unstructured":"Alkafaas SS, Elsalahaty MI, Ismail DF et al. The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target. Cancer Cell Int. 2024;24:89.","journal-title":"Cancer Cell Int."},{"key":"9091_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1042\/BJ20111929","volume":"444","author":"ME Schnute","year":"2012","unstructured":"Schnute ME, McReynolds MD, Kasten T et al. Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012;444:79\u201388.","journal-title":"Biochem J."},{"key":"9091_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.bbrc.2016.01.053","volume":"470","author":"T Ju","year":"2016","unstructured":"Ju T, Gao D, Fang ZY. Targeting colorectal cancer cells by a novel sphingosine kinase 1 inhibitor PF-543. Biochem Biophys Res Commun. 2016;470:728\u2013734.","journal-title":"Biochem Biophys Res Commun."},{"key":"9091_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5483\/BMBRep.2012.45.9.186","volume":"45","author":"EW Lee","year":"2012","unstructured":"Lee EW, Seo J, Jeong M, Lee S, Song J. The roles of FADD in extrinsic apoptosis and necroptosis. BMB Rep. 2012;45:496\u2013508.","journal-title":"BMB Rep."},{"key":"9091_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1074-7613(00)80211-3","volume":"12","author":"MR Sprick","year":"2000","unstructured":"Sprick MR, Weigand MA, Rieser E et al. FADD\/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 2000;12:599\u2013609.","journal-title":"Immunity."},{"key":"9091_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0092-8674(00)81590-1","volume":"94","author":"H Li","year":"1998","unstructured":"Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491\u2013501.","journal-title":"Cell."},{"key":"9091_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0014-5793(98)00061-1","volume":"423","author":"VP Skulachev","year":"1998","unstructured":"Skulachev VP. Cytochrome c in the apoptotic and antioxidant cascades. FEBS Lett. 1998;423:275\u2013280.","journal-title":"FEBS Lett."},{"key":"9091_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.cell.2005.05.011","volume":"122","author":"M Giorgio","year":"2005","unstructured":"Giorgio M, Migliaccio E, Orsini F et al. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. Cell. 2005;122:221\u2013233.","journal-title":"Cell."},{"key":"9091_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc2875","volume":"10","author":"NJ Pyne","year":"2010","unstructured":"Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010;10:489\u2013503.","journal-title":"Nat Rev Cancer."},{"key":"9091_CR32","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.1038\/s41598-025-88328-2","volume":"15","author":"Z Song","year":"2025","unstructured":"Song Z, Zhao Z, Liu X et al. Sphingosine kinase 1 promotes M2 macrophage infiltration and enhances glioma cell migration via the JAK2\/STAT3 pathway. Sci Rep. 2025;15:4152.","journal-title":"Sci Rep."},{"key":"9091_CR33","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3892\/ijmm.2020.4796","volume":"47","author":"Y Ma","year":"2021","unstructured":"Ma Y, Xing X, Kong R et al. SphK1 promotes development of non-small cell lung cancer through activation of STAT3. Int J Mol Med. 2021;47:374\u2013386.","journal-title":"Int J Mol Med."},{"key":"9091_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1172\/JCI36183","volume":"119","author":"M Zeisberg","year":"2009","unstructured":"Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429\u20131437.","journal-title":"J Clin Invest."},{"key":"9091_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrc776","volume":"2","author":"FH Igney","year":"2002","unstructured":"Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277\u2013288.","journal-title":"Nat Rev Cancer."},{"key":"9091_CR36","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1136\/gut.2004.052704","volume":"53","author":"AJ Watson","year":"2004","unstructured":"Watson AJ. Apoptosis and colorectal cancer. Gut. 2004;53:1701\u20131709.","journal-title":"Gut."},{"key":"9091_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188623","volume":"1876","author":"M Luo","year":"2021","unstructured":"Luo M, Yang X, Chen HN, Nice EC, Huang C. Drug resistance in colorectal cancer: An epigenetic overview. Biochim Biophys Acta Rev Cancer. 2021;1876:188623.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"9091_CR38","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","volume":"28","author":"RS Herbst","year":"2010","unstructured":"Herbst RS, Eckhardt SG, Kurzrock R et al. Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28:2839\u20132846.","journal-title":"J Clin Oncol."},{"key":"9091_CR39","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","volume":"28","author":"JC Soria","year":"2010","unstructured":"Soria JC, Smit E, Khayat D et al. Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010;28:1527\u20131533.","journal-title":"J Clin Oncol."},{"key":"9091_CR40","doi-asserted-by":"publisher","first-page":"13879","DOI":"10.1039\/C7NR04959E","volume":"9","author":"X Wu","year":"2017","unstructured":"Wu X, Wang S, Li M et al. Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy. Nanoscale. 2017;9:13879\u201313904.","journal-title":"Nanoscale."},{"key":"9091_CR41","first-page":"123","volume":"1805","author":"B Pennarun","year":"2010","unstructured":"Pennarun B, Meijer A, de Vries EG, Kleibeuker JH, Kruyt F, de Jong S. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim Biophys Acta. 2010;1805:123\u2013140.","journal-title":"Biochim Biophys Acta."},{"key":"9091_CR42","first-page":"1897","volume":"54","author":"SL Kim","year":"2019","unstructured":"Kim SL, Min IS, Park YR, Lee ST, Kim SW. [Corrigendum] Lipocalin 2 inversely regulates TRAIL sensitivity through p38 MAPK-mediated DR5 regulation in colorectal cancer. Int J Oncol. 2019;54:1897.","journal-title":"Int J Oncol."},{"key":"9091_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.cdd.4401187","volume":"10","author":"HN LeBlanc","year":"2003","unstructured":"LeBlanc HN, Ashkenazi A. Apo2L\/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66\u201375.","journal-title":"Cell Death Differ."},{"key":"9091_CR44","doi-asserted-by":"publisher","first-page":"8628","DOI":"10.1038\/sj.onc.1207232","volume":"22","author":"S Wang","year":"2003","unstructured":"Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003;22:8628\u20138633.","journal-title":"Oncogene."},{"key":"9091_CR45","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.277.5327.818","volume":"277","author":"JP Sheridan","year":"1997","unstructured":"Sheridan JP, Marsters SA, Pitti RM et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818\u2013821.","journal-title":"Science."},{"key":"9091_CR46","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1007\/s12035-020-01978-3","volume":"57","author":"W Jin","year":"2020","unstructured":"Jin W, Xu W, Zhang XX, Ren CC. Ischemic Preconditioning Upregulates Decoy Receptors to Protect SH-SY5Y Cells from OGD Induced Cellular Damage by Inhibiting TRAIL Pathway and Agitating PI3K\/Akt Pathway. Mol Neurobiol. 2020;57:3658\u20133670.","journal-title":"Mol Neurobiol."},{"key":"9091_CR47","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3892\/or.2015.3793","volume":"33","author":"JK Woo","year":"2015","unstructured":"Woo JK, Kang JH, Jang YS et al. Evaluation of preventive and therapeutic activity of novel non-steroidal anti-inflammatory drug, CG100649, in colon cancer: Increased expression of TNF-related apoptosis-inducing ligand receptors enhance the apoptotic response to combination treatment with TRAIL. Oncol Rep. 2015;33:1947\u20131955.","journal-title":"Oncol Rep."},{"key":"9091_CR48","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1080\/15384047.2015.1056944","volume":"16","author":"J Yang","year":"2015","unstructured":"Yang J, Yang C, Zhang S et al. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer. Cancer Biol Ther. 2015;16:1194\u20131204.","journal-title":"Cancer Biol Ther."},{"key":"9091_CR49","doi-asserted-by":"publisher","first-page":"11667","DOI":"10.1158\/0008-5472.CAN-05-2702","volume":"65","author":"D Pchejetski","year":"2005","unstructured":"Pchejetski D, Golzio M, Bonhoure E et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005;65:11667\u201311675.","journal-title":"Cancer Res."},{"key":"9091_CR50","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/j.1349-7006.2012.02335.x","volume":"103","author":"YL Yang","year":"2012","unstructured":"Yang YL, Ji C, Cheng L et al. Sphingosine kinase-1 inhibition sensitizes curcumin-induced growth inhibition and apoptosis in ovarian cancer cells. Cancer Sci. 2012;103:1538\u20131545.","journal-title":"Cancer Sci."},{"key":"9091_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202104452","volume":"9","author":"P Gupta","year":"2022","unstructured":"Gupta P, Kadamberi IP, Mittal S et al. Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer. Adv Sci (Weinh). 2022;9:e2104452.","journal-title":"Adv Sci (Weinh)."},{"key":"9091_CR52","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1016\/j.ejca.2006.07.006","volume":"42","author":"JP Spano","year":"2006","unstructured":"Spano JP, Milano G, Rixe C, Fagard R. JAK\/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer. 2006;42:2668\u20132670.","journal-title":"Eur J Cancer."},{"key":"9091_CR53","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1593\/neo.07971","volume":"10","author":"H Xiong","year":"2008","unstructured":"Xiong H, Zhang ZG, Tian XQ et al. Inhibition of JAK1, 2\/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008;10:287\u2013297.","journal-title":"Neoplasia."},{"key":"9091_CR54","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/nm.2250","volume":"16","author":"H Lee","year":"2010","unstructured":"Lee H, Deng J, Kujawski M et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010;16:1421\u20131428.","journal-title":"Nat Med."},{"key":"9091_CR55","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.celrep.2014.02.016","volume":"6","author":"SJ Priceman","year":"2014","unstructured":"Priceman SJ, Shen S, Wang L et al. S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3. Cell Rep. 2014;6:992\u2013999.","journal-title":"Cell Rep."},{"key":"9091_CR56","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","volume":"23","author":"J Liang","year":"2013","unstructured":"Liang J, Nagahashi M, Kim EY et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23:107\u2013120.","journal-title":"Cancer Cell."},{"key":"9091_CR57","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ijc.21355","volume":"118","author":"S Hiscox","year":"2006","unstructured":"Hiscox S, Jiang WG, Obermeier K et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006;118:290\u2013301.","journal-title":"Int J Cancer."},{"key":"9091_CR58","first-page":"277","volume":"31","author":"H Kajiyama","year":"2007","unstructured":"Kajiyama H, Shibata K, Terauchi M et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31:277\u2013283.","journal-title":"Int J Oncol."},{"key":"9091_CR59","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1158\/1535-7163.MCT-10-0582","volume":"9","author":"RK Srivastava","year":"2010","unstructured":"Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther. 2010;9:3254\u20133266.","journal-title":"Mol Cancer Ther."},{"key":"9091_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099067","volume":"9","author":"H Wang","year":"2014","unstructured":"Wang H, Xu C, Kong X et al. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. Plos One. 2014;9:e99067.","journal-title":"Plos One."},{"key":"9091_CR61","doi-asserted-by":"publisher","first-page":"18208","DOI":"10.1038\/srep18208","volume":"5","author":"JW Chang","year":"2015","unstructured":"Chang JW, Kang SU, Shin YS et al. Combination of NTP with cetuximab inhibited invasion\/migration of cetuximab-resistant OSCC cells: Involvement of NF-kappaB signaling. Sci Rep. 2015;5:18208.","journal-title":"Sci Rep."},{"key":"9091_CR62","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2024.5401","author":"Z Yang","year":"2024","unstructured":"Yang Z, Liu H, Song Y et al. Luteolin enhances drug chemosensitivity by downregulating the FAK\/PI3K\/AKT pathway in paclitaxel-resistant esophageal squamous cell carcinoma. Int J Mol Med. 2024. https:\/\/doi.org\/10.3892\/ijmm.2024.5401.","journal-title":"Int J Mol Med."},{"key":"9091_CR63","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1177\/0091270005276905","volume":"45","author":"VS Donnenberg","year":"2005","unstructured":"Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol. 2005;45:872\u2013877.","journal-title":"J Clin Pharmacol."},{"key":"9091_CR64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrc2499","volume":"8","author":"JE Visvader","year":"2008","unstructured":"Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755\u2013768.","journal-title":"Nat Rev Cancer."},{"key":"9091_CR65","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","volume":"11","author":"L Walcher","year":"2020","unstructured":"Walcher L, Kistenmacher AK, Suo H et al. Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Front Immunol. 2020;11:1280.","journal-title":"Front Immunol."},{"key":"9091_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112448","author":"S Mahajan-Thakur","year":"2017","unstructured":"Mahajan-Thakur S, Bien-Moller S, Marx S, Schroeder H, Rauch BH. Sphingosine 1-phosphate (S1P) signaling in glioblastoma multiforme-A systematic review. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18112448.","journal-title":"Int J Mol Sci."},{"key":"9091_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13111132","author":"J Xu","year":"2023","unstructured":"Xu J, Zhou L, Du X et al. Transcriptome and Lipidomic Analysis Suggests Lipid Metabolism Reprogramming and Upregulating SPHK1 Promotes Stemness in Pancreatic Ductal Adenocarcinoma Stem-like Cells. Metabolites. 2023. https:\/\/doi.org\/10.3390\/metabo13111132.","journal-title":"Metabolites."},{"key":"9091_CR68","doi-asserted-by":"publisher","first-page":"46801","DOI":"10.18632\/oncotarget.8695","volume":"8","author":"N Mukherjee","year":"2017","unstructured":"Mukherjee N, Lu Y, Almeida A et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017;8:46801\u201346817.","journal-title":"Oncotarget."},{"key":"9091_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2020.101380","volume":"65","author":"Z Chen","year":"2020","unstructured":"Chen Z, Liu B. Sphk1 participates in malignant progression of breast cancer by regulating epithelial-mesenchymal transition and stem cell characteristics. Tissue Cell. 2020;65:101380.","journal-title":"Tissue Cell."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09091-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09091-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09091-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:03:12Z","timestamp":1757948592000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09091-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9091"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09091-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}